The Journal of heart and lung transplantation : the official publication of the International Society for Heart TransplantationReview

undefined Jan 2025

A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension.

Abstract

Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high.

Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence.

This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.

References:

Galiè N, Channick RN, Frantz RP, et al.: Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019;53.
Badesch DB, McLaughlin VV, Delcroix M, et al.: Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:56s–61s.
Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ: Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62s–7s.
Ghofrani HA, Pepke-Zaba J, Barbera JA, et al.: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:68s–72s.
Zelt JGE, Sugarman J, Weatherald J, et al.: Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era. Eur Respir J 2022;59.

Article info

Journal issue:

Volume: 44
Issue: 1

Doi:

10.1016/j.healun.2024.09.021

More resources:

Elsevier Science

Full Text Sources

Paid